Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034 22/09/2023

1,090 USD (-2,68%)

(-2,68%) 22/09/2023

Grafiek Rigel Pharmaceuticals

Grafiek Rigel Pharmaceuticals

1 dag1d -2,68%
1 week1w 1,87%
1 maand1m -8,40%
3 maanden3m -35,12%
6 maanden6m -14,84%
1 jaar1j -0,91%
5 jaar5j -66,97%

Rigel Pharmaceuticals in het nieuws

Toon enkel gratis nieuws

20 september 2023 · Rigel to Present at the 2023 Cantor Global Healthcare Conference · Persbericht

30 augustus 2023 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

1 augustus 2023 · Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update · Persbericht

25 juli 2023 · Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update · Persbericht

5 juli 2023 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

7 juni 2023 · Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML · Persbericht

6 juni 2023 · Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances · Persbericht

1 juni 2023 · Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting · Persbericht

31 mei 2023 · Rigel to Present at the Jefferies 2023 Global Healthcare Conference · Persbericht

2 mei 2023 · Rigel Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

Profiel Rigel Pharmaceuticals

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.rigel.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: Raul Rodriguez

Werknemers: 280

Aandelen Rigel Pharmaceuticals

Beurswaarde: 195,29 miljoen USD

Effecten: 174,36 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 0,90

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe